Articles with "carfilzomib induced" as a keyword



Photo by myriamzilles from unsplash

Carfilzomib-induced thrombotic microangiopathy: A case based review.

Sign Up to like & get
recommendations!
Published in 2020 at "Hematology/oncology and stem cell therapy"

DOI: 10.1016/j.hemonc.2020.07.001

Abstract: Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and… read more here.

Keywords: treatment; case; carfilzomib induced; carfilzomib ... See more keywords
Photo from wikipedia

Apremilast ameliorates carfilzomib‐induced pulmonary inflammation and vascular injuries

Sign Up to like & get
recommendations!
Published in 2019 at "International Immunopharmacology"

DOI: 10.1016/j.intimp.2018.11.023

Abstract: &NA; Acute lung injury (ALI) due to chemotherapy occurs frequently. It presents a challenge for clinicians managing therapies for different types of cancers. Carfilzomib (Kyprolis™) is a new proteasome inhibitor that shows promise for the… read more here.

Keywords: carfilzomib induced; induced lung; lung injury; inflammation ... See more keywords
Photo from wikipedia

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion.

Sign Up to like & get
recommendations!
Published in 2018 at "Blood advances"

DOI: 10.1182/bloodadvances.2018027532

Abstract: Rapid initiation of eculizumab mitigates progression of carfilzomib-induced aHUS. Development of carfilzomib-induced aHUS may be associated with heterozygous CFHR3-CFHR1 deletion. read more here.

Keywords: cfhr3 cfhr1; induced ahus; may associated; heterozygous cfhr3 ... See more keywords
Photo from wikipedia

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin

Sign Up to like & get
recommendations!
Published in 2021 at "International Journal of Molecular Sciences"

DOI: 10.3390/ijms222010956

Abstract: Background: Carfilzomib is a first-line proteasome inhibitor indicated for relapsed/refractory multiple myeloma (MM), with its clinical use being hampered by cardiotoxic phenomena. We have previously established a translational model of carfilzomib cardiotoxicity in young adult… read more here.

Keywords: metformin; carfilzomib induced; model; cardiotoxicity ... See more keywords